Last reviewed · How we verify
PF-07202954 Single Dose (pf-07202954-single-dose)
PF-07202954 Single Dose is a marketed drug by Pfizer Inc. for Hemophilia A and Hemophilia A with inhibitors. It has generated $21.2B in revenue. The mechanism of action is not specified on Wikipedia. This drug has clinical differentiation in treating Hemophilia A with inhibitors. Its commercial significance is substantial due to its revenue. There are no pipeline developments mentioned.
At a glance
| Generic name | pf-07202954-single-dose |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
Approved indications
- Hemophilia A
- Hemophilia A with inhibitors
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A inhibitors
- Strong CYP3A inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C9 inhibitors
- CYP2C9 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07202954 Single Dose CI brief — competitive landscape report
- PF-07202954 Single Dose updates RSS · CI watch RSS
- Pfizer portfolio CI